hiPSC-derived neural microtissues / TreeFrog Therap - LARVOL DELTA

TreeFrog Publishes Results of First Successful Bioproduction of a Parkinson’s Disease Cell Therapy in Scalable Bioreactor in Neurotherapeutics Journal (Businesswire) - "TreeFrog Therapeutics...today published an article in Neurotherapeutics, demonstrating the first successful bioproduction of a Parkinson’s Disease cell therapy in a scalable bioreactor, leading to full behavioral recovery 16 weeks after transplantation using a cryopreserved 3D microtissue format...'Today’s publication demonstrates how TreeFrog Therapeutics has overcome the most complex challenges of developing a successful treatment for Parkinson’s disease using our C-Stem platform technology and producing a therapy containing mature dopaminergic neurons with a unique 3D format that promotes cell survival post-graft with proven pre-clinical results.'...The results published today, demonstrate the same efficacy with the cryopreserved product, as the fresh product, with no time-to-effect delay."

Commercial • Preclinical • CNS Disorders • Parkinson's Disease

TREEFROG PRESENTS DATA FROM THEIR PARKINSON’S DISEASE CELL THERAPY PROGRAM AT THE 29TH WORLD CONGRESS ON PARKINSON’S DISEASE AND RELATED DISORDERS (IAPRD) IN LISBON (PRNewswire) - "TreeFrog Therapeutics will participate for the first time at the IAPRD, to present data from their Parkinson's disease cell therapy program, which has demonstrated excellent results with full motor recovery at 16 weeks in preclinical studies....'The data we are presenting reports on the first bioproduction of a cell therapy for the disease in a scalable bioreactor. In pre-clinical models, full behavioral recovery was observed by 16 weeks post transplantation and dopaminergic neurons were seen projecting into the host striatum.'"

Preclinical • CNS Disorders • Parkinson's Disease